15 completed, 8 unknown, 6 recruiting, 3 active not recruiting. 36 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 15, Unknown 8, Recruiting 6, Active not recruiting 3, Not yet recruiting 2, Terminated 2 |
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Unknown 1 |
Follow Population Groups: new trials by email Literature Review of Population Groups trials Research Report on Population Groups
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety, Tolerability, Pharmacokinetics of VV147 Tablets in Chinese Healthy Participants. VV147 15mg Group, VV147 30mg Group, VV147 60mg Group - Healthy Participants | Phase 1 | Not yet recruiting | Vigonvita Life Sciences | 48 | 2026-10-20 | 2026-10-21 |
| Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg - Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus) | Phase 1 | Not yet recruiting | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 90 | 2026-07-01 | 2026-06-10 |
| A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders JL18008 20 μg/kg, Placebo (for 20 μg/kg Group), JL18008 40 μg/kg - HIV Infections | Phase 1 / Phase 2 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 30 | 2026-05-26 | 2026-08-06 |
| Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants VV913 1mg group, VV913 2mg group, VV913 4mg group - Healthy Volunteers | Phase 1 | Recruiting | Vigonvita Life Sciences | 56 | 2026-01-29 | 2026-05-04 |
| Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers VV261 5mg group, VV261 20mg Group, VV261 50mg group - Healthy Volunteers | Phase 1 | Completed | Vigonvita Life Sciences | 66 | 2026-01-04 | 2026-11-09 |
| Comparison of Analgesic Efficacy Between Ultrasound Guided Serratus Anterior Plane Block or Thoracic Paravertebral Block Versus Intravenous Fentanyl for On-pump Coronary Artery Bypass Graft Surgery Serratus Anterior Plane Block (SAPB) group, Thoracic paravertebral block (TPVB), Intravenous fentanyl 1 μg∙kg-1 - Intra and Post Operative Pain Management, Fast Track Program,(Enhanced Recovery After Surgery (ERAS)) | Phase 1 | Active not recruiting | Ain Shams University | 111 | 2026-01-01 | 2026-11-12 |
| Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants CIGB-814 (single-dose group), CIGB-814 placebo (single-dose group), CIGB-814 (multiple-dose group) - Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Yi Fang | 70 | 2025-08-18 | 2025-09-19 |
| Comparing Nebulized Ketamine,Nebulized Ketamine and Precedex and IM Ketamine for Analgesia in Pediatric Burn Group (1): Patients will receive nebulized ketamine (2 mg/kg), Group (2): Patients will receive nebulized combination of dexmedetomidine and ketamine (1 μg/kg + 1 mg/kg), Patients will receive intramuscular ketamine (4 mg/kg, intramuscularly) 15 mins before starting the procedure. - Inhalation Anesthesia | Phase 1 | Active not recruiting | Ain Shams University | 60 | 2025-04-16 | 2025-07-25 |
| Evaluation of Postoperative Pain in Cases Undergoing Cataract Surgery Under Topical Versus General Anesthesia Topical Anaesthesia group, General Anaesthesia group - Topical Anaesthesia, General Anesthetic Drug Adverse Reaction | Phase 1 / Phase 2 | Active not recruiting | Alexandria University | 50 | 2025-04-02 | 2025-12-17 |
| rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage Low dose group, Medium dose group, High dose group - Intraventricular Hemorrhage | Phase 1 | Recruiting | Beijing Tiantan Hospital | 18 | 2025-03-01 | 2025-02-27 |
| The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study Pyrotinib low dose group, Pyrotinib normal dose group - Breast Cancer | Phase 1 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2024-11-01 | 2025-01-13 |
| To Evaluate the Safety of JL18008 JL18008 1 μg/kg, JL18008 5 μg/kg, JL18008 10 μg/kg - HIV Infections | Phase 1 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 40 | 2024-06-13 | 2026-06-11 |
| Clinical Trial of the Effect of Methoxyethyl Etomidate Hydrochloride on the QT Interval of the Heart ET-26 0.8mg/kg(low-dose) group, ET-26 2.8mg/kg(high dose) group - QT Interval, Variation in | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 18 | 2023-11-09 | 2025-02-14 |
| Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects Test drug XT1061 capsules and placebo,Single dose group, Test drug XT1061 capsules and placebo,Multiple dosing group, Test drug XT1061 capsules and placebo,Food Impact Group - Chronic Hepatitis b | Phase 1 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 128 | 2023-07-18 | 2024-02-28 |
| A Phase I SAD/MAD and Liver Effect Study of Vitalangio in Venous Thromboembolism Patients . Placebo Comparator: Single dose group, Experimental: Food effect group, Active Comparator: Multiple dose group - Thrombosis, Cardiovascular Diseases | Phase 1 | Completed | Peking University First Hospital | 627 | 2023-06-20 | 2026-06-01 |
| RAB001(LLP2A-Ale) in Healthy Subjects RAB001 400 μg/kg group, RAB001 750 μg/kg group, Normal saline - Osteonecrosis of the Femoral Head | Phase 1 | Completed | ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | 16 | 2023-02-10 | 2026-04-22 |
| Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects Low dose group, High dose group - Advanced Breast Cancer | Phase 1 | Completed | Ahon Pharmaceutical Co., Ltd. | 18 | 2022-11-11 | 2024-03-04 |
| Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers TPN171H 10 mg Group, TPN171H 30 mg Group, TPN171H 40 mg Group - Healthy Subjects | Phase 1 | Completed | Vigonvita Life Sciences | 32 | 2022-10-10 | 2023-04-05 |
| NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection Autologous memory lymphocyte Injection (NewishT), low-dose group, Autologous memory lymphocyte Injection (NewishT), high-dose group - Hepatocellular Carcinoma | Phase 1 | Unknown | Newish Technology (Beijing) Co., Ltd. | 26 | 2022-07-26 | 2023-09-28 |
| Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers VV116 200 mg Group, VV116 400mg Group, VV116 600mg Group - Healthy Subjects | Phase 1 | Completed | Vigonvita Life Sciences | 36 | 2021-12-14 | 2022-02-09 |
Showing 20 of 36. Sign in to see all of them.
Coronavirus Infections (3) · HIV Infections (2) · Pain, Postoperative (2) · Acute Lung Injury (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Breast Neoplasms (1) · Bronchiectasis (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Cataract (1) · Cerebral Palsy (1) · Depressive Disorder, Major (1) · Hemangioma, Capillary (1)
Vigonvita Life Sciences (6) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (3) · Ahon Pharmaceutical Co., Ltd. (2) · Ain Shams University (2) · Jecho Biopharmaceuticals Co., Ltd. (2) · Alexandria University (1) · Alice K. Gong (1) · Assaf-Harofeh Medical Center (1) · Beijing Tiantan Hospital (1) · Daniel Jerković (1) · Haukeland University Hospital (1) · Imam Abdulrahman Bin Faisal University (1) · Luye Pharma Group Ltd. (1) · Mansoura University (1) · Newish Technology (Beijing) Co., Ltd. (1)
China (22) · Egypt (4) · United States (3) · Brazil (1) · Croatia (1) · Israel (1) · Norway (1) · Saudi Arabia (1)
Gangyi Liu (2) · Huan Zhou (2) · Ada C. Gastaldi, doctor (1) · Alice K Gong, M.D. (1) · Alice K Gong, MD (1) · Chunde Bao, M.D. & Ph.D. (1) · Haiyan Li, MD (1) · Hatem Qutub, MD (1) · Hong Ren, master (1) · Jianqiang Cai (1) · Jing Zhang (1) · Marcellus Dias da Costa, Infectious disease physician (1) · Margrethe Vika, AP (1) · Marihan A Lwiz, MBBCH,M.Sc. (1)
PMID 11978924, PMID 1280928, PMID 24506509, PMID 24690891, PMID 28733314, PMID 29417902, PMID 30922152, PMID 32436160, PMID 33773111, PMID 36803632, PMID 39188943, PMID 9674466